Language

Pulmonary Research

Innovative Therapies Close to Home

MultiCare Pulmonary Specialists is a multi-physician group located in Tacoma, WA. The site employs an experienced research team comprised of board certified Pulmonologists, Study Coordinators, and an Administrative Assistant. The site is conveniently located near three hospitals and all clinical research is done on site. In addition, the site has a comprehensive patient database that is connected to all MultiCare facilities.

Pulmonary studies include the following therapeutic areas:

  • Asthma
  • Allergy & Allergic Rhinitis
  • COPD
  • Smoking Cessation
  • Sleep Disorders
  • Cystic Fibrosis
  • Bronchiectasis

Principal Investigator:

Sub-Investigators:

Pulmonary Studies Accepting Participants

Adults

COPD

Ethos

Study Number: PT010005-01—A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.

Study Info 

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Juanita Baker, [email protected], 253-403-0366


Chiesi

Study Number: CCD-0599AA3-02—A 6-week, multi-center, randomized, double-blind, placebo-and active-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide via Pressurized Metered Dose Inhaler) in subjects with chronic obstructive pulmonary disease (COPD).

Study Info 

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389


TRELEGY

Study Number: GSK 207609 - A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease

Study Info

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Asthma

ANDHI

Study Number: D3250C00045—A multi-center, randomized, double-blind, parallel group, placebo-controlled, Phase 3b study to evaluate the safety and efficacy of the Benralizumab 30 mg sc in patients with severe asthma uncontrolled on standard of care treatment.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389


PT001102

Study Number: PT001102 - A randomized, double-blind, parallel group, multicenter, 24-week study comparing the efficacy and safety of three doses of PT001 to placebo and open label Spiriva Respimat.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389


CHRONICLE

Study Number: D3250R00023 - A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Influenza A

Emergent Biosolutions

Study Number: IA-001 - A randomized, double-blind, placebo-controlled, dose-ranging study evaluating the safety, pharmacokinetics and clinical benefit of FLUIGIV in hospitalized patients with serious Influenza A infection.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366


VISTERRA

Study Number: VIS410-203 - A Phase 2b, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of Intravenous VIS410 in addition to Oseltamivir (Tamiflu®) compared with Oseltamivir alone in hospitalized adults with Influenza A Infection requiring oxygen support.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Non-Cystic Fibrosis Bronchiectasis

The Willow Study

Study Number: INS1007-201 - A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, tolerability and pharmacokinetics of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis bronchiectasis.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366

Idiopathic Pulmonary Fibrosis

SPIRIT

Study Number: BIOGEN 203PF203 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Pulmonary Sarcoidosis

NDS-CP-001

Study Number: NDS-CP-001 - A multicenter, open-label study to estimate the effect sizes of HRCT endpoints in response to Glucocorticoid induction therapy in subjects with pulmonary sarcoidosis.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Chronic Cough

MERCK MK-7264-030

Study Number: MERCK MK-7264-030 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366

Pediatrics

Idiopathic Bilateral Cataracts

CTX Prevalence Study

Study Number: 018CTXX15001—An observational, multi-center study of the prevalence of cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts.

Study Info

Principal Investigator(s): Michael Raff, MD

Study Coordinator: Dalia Sherif, [email protected], 253-403-2698